Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808961 · ClinicalTrials.gov registry record · NA
Low Dose Niacin (Vitamin B3) for Parkinson's Disease
A NA study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03808961: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT03808961 is a NA study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03808961, a NA study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
(1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Niacinamide
- DIETARY_SUPPLEMENT Niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2023-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808961
The ClinicalTrials.gov registry entry for NCT03808961 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03808961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03808961 about?
NCT03808961 is a clinical study titled "Low Dose Niacin (Vitamin B3) for Parkinson's Disease". (1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.
What is the current status of trial NCT03808961?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2020-01-01. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT03808961?
The interventions under investigation include: Placebo (OTHER), Niacinamide (DIETARY_SUPPLEMENT), Niacin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03808961?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.